Daniel Tillett Buys 400,000 Shares of Race Oncology (ASX:RAC) Stock

Race Oncology Limited (ASX:RAC) insider Daniel Tillett purchased 400,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was bought at an average price of A$1.25 per share, for a total transaction of A$500,000.00.

Daniel Tillett also recently made the following trade(s):

• On Thursday, December 18th, Daniel Tillett acquired 12,218 shares of Race Oncology stock. The shares were bought at an average cost of A$2.58 per share, with a total value of A$31,534.66.
• On Thursday, December 18th, Daniel Tillett bought 300,000 shares of Race Oncology stock. The stock was bought at an average cost of A$1.25 per share, for a total transaction of A$375,000.00.
• On Wednesday, November 26th, Daniel Tillett bought 22,000 shares of Race Oncology stock. The stock was bought at an average cost of A$2.67 per share, for a total transaction of A$58,740.00.

Race Oncology Price Performance

The company has a market capitalization of $211.94 million, a P/E ratio of -14.60 and a beta of 1.74.

About Race Oncology

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein).